Moderna Attracts Heavy Call Option Activity as Market Bets on Biotech Upside
Key Insights
A large call option trade on Moderna (MRNA.US) was detected with a volume of 1,998 contracts against open interest of just 29, yielding a V/OI ratio of 68.9.
The trade carried a premium of $669,330 with a strike price of $74.00 and an expiration date of July 10, 2026.
The unusually high volume-to-open-interest ratio signals concentrated bullish sentiment on Moderna among options traders.
A surge of unusual options activity swept through the final hours of trading on July 1, with Moderna (MRNA.US) emerging as a standout among pharmaceutical equities attracting concentrated market bets. According to options flow data, a trade on Moderna call contracts registered a volume of 1,998 — vastly exceeding the open interest of just 29 contracts — producing a volume-to-open-interest (V/OI) ratio of 68.9.
The transaction carried a premium of $669,330, reflecting substantial capital commitment. The strike price was set at $74.00, with an expiration date of July 10, 2026, giving the position a nine-day window from the time of detection. Such elevated V/OI ratios are widely interpreted by market participants as signals of informed or conviction-driven positioning, particularly when observed in the options market during volatile trading sessions.
The Moderna trade was one of ten high V/OI ratio options detected in the last two hours of the July 1 session. By comparison, a put contract on Microsoft (MSFT.US) posted the highest ratio of the session at 77.95, with a volume of 1,559 against open interest of 20 and a premium of $584,650. A call trade on Shell (SHEL.US) also drew attention with a volume of 10,000 contracts versus open interest of 156, yielding a V/OI ratio of 64.1 on a $100,000 premium.
The clustering of outsized call activity in Moderna — a company whose pipeline spans mRNA-based vaccines and therapeutics across infectious diseases, oncology, and rare conditions — underscores the heightened sensitivity of biotech equities to both clinical catalysts and broader market sentiment. While the specific motivation behind the trade remains unknown, the size and structure of the position suggest a directional wager on near-term upside in the stock.
Options market analysts note that V/OI ratios of this magnitude often reflect institutional positioning or hedging activity tied to anticipated events. With the contract expiring on July 10, 2026, the trade's nine-day runway implies a tactical rather than long-term strategic horizon.